Last reviewed · How we verify
GADOTERIC ACID
Gadoteric acid works by altering the magnetic properties of MRI images to enhance contrast.
Gadoteric acid is a small molecule drug of the gadolinium class, used as a contrast agent in magnetic resonance imaging (MRI). Its exact target is unknown, but it is believed to work by enhancing the contrast of MRI images through magnetic properties. The commercial status of gadoteric acid is unclear, and it may be patented or have generic manufacturers. Key safety considerations include the potential for nephrogenic systemic fibrosis in patients with severe kidney disease. Further research is needed to fully understand the pharmacology and safety of this drug.
At a glance
| Generic name | GADOTERIC ACID |
|---|---|
| Drug class | gadoteric acid |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Mechanism of action
Imagine you're trying to take a picture of a dark room. Without any light, it's hard to see anything. Gadoteric acid is like a special light that helps the MRI machine see inside the body more clearly, by making the magnetic signals stronger and more visible.
Approved indications
Common side effects
Key clinical trials
- Multiparametric MRI Assessment of Atrial Heart Disease as a Predictor of Atrial Fibrillation After Myocardial Revascularization Surgery (NA)
- Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas (PHASE3)
- ELUDYN: Assessment of Intra-individual Variability of Vascular Dynamics of Gadopiclenol Injection Parameters in Contrast-enhanced MRI (PHASE4)
- Mangafodipir - an Intracellular Contrast Agent for Magnetic Resonance Imaging (MRI): Measuring Manganese Uptake Rate in Heart Failure Patients With Preserved Ejection Fraction (HFpEF) Patients. (PHASE2)
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) (PHASE3)
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems (PHASE3)
- Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders (NA)
- Kinetics of Urinary Excretion of Gadolinium Contrast Agents Used in MRI Examinations (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GADOTERIC ACID CI brief — competitive landscape report
- GADOTERIC ACID updates RSS · CI watch RSS